STOCK TITAN

[SCHEDULE 13G/A] Beta Bionics, Inc. Amended Passive Investment Disclosure

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Beta Bionics Inc ownership disclosure: The Vanguard Group reports beneficial ownership of 0 shares of Common Stock, representing 0% of the class as of 03/13/2026.

The filing is an amendment (Schedule 13G/A) reflecting an internal realignment at The Vanguard Group and states certain subsidiaries will report separately in reliance on SEC Release No. 34-39538. The form is signed by Ashley Grim on 03/26/2026.

Positive

  • None.

Negative

  • None.

Insights

Filing shows no beneficial stake by The Vanguard Group in Beta Bionics.

The Schedule 13G/A amends prior reporting to state 0 shares owned and 0% ownership as of 03/13/2026. The filing attributes the change to an internal realignment and reliance on SEC Release No. 34-39538 for disaggregated reporting.

Cash-flow treatment or trading intent is not stated; subsequent filings from the reporting entities may disclose holdings if they report separately.

Amendment clarifies reporting structure under SEC guidance.

The text cites SEC Release No. 34-39538 and explains subsidiaries or business divisions will report beneficial ownership separately from The Vanguard Group, Inc. This explains the zero ownership entry rather than an explicit sale or acquisition.

Investors should note the filing is procedural: it documents reporting alignment changes and includes the preparer signature dated 03/26/2026.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release. These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment. Further in accordance with SEC Release No. 34-39538 (January 12, 1998), The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.


SCHEDULE 13G



The Vanguard Group
Signature:Ashley Grim
Name/Title:Head of Global Fund Administration
Date:03/26/2026
Beta Bionics, Inc.

NASDAQ:BBNX

View BBNX Stock Overview

BBNX Rankings

BBNX Latest News

BBNX Latest SEC Filings

BBNX Stock Data

501.96M
41.93M
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
IRVINE